|
TACT833
TACT833 is a monoamine transporter transporter modulator, modulator and serotonin 5-HT1B receptor, 5-HT1B receptor receptor modulator, modulator which is under development for the treatment of alcohol use disorder, anorexia, and binge-eating disorder. It is being developed by Tactogen. As of the first quarter of 2025, the drug is in the preclinical research stage of development. See also * TACT411 * TACT908 * 1Z2MAP1O * List of investigational hallucinogens and entactogens References 5-HT1B agonists Drugs with undisclosed chemical structures Entactogens Experimental entactogens Monoamine releasing agents {{Psychoactive-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Experimental Entactogens
This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. ''Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.'' The list also includes non-hallucinogenic drugs related to hallucinogens, such as non-hallucinogenic serotonin 5-HT2A receptor agonists and non-hallucinogenic ketamine analogues. Cannabinoids, or cannabinoid receptor modulators, are not included in this list. Many of the indications are not for continuous medication therapy but rather are for medication-assisted psychotherapy or short-term use only. The section that the drug is in corresponds to its highest developmental phase, not its phase for all listed indications. This list was last comprehensively updated in October 2024. It is likely to become outdated with time. Under development Preregistration * Midomafetamine (MDMA ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |